Adalimumab (anti-TNF-alpha) is the first fully human recombinant IgG1 monoclonal antibody that specifically targets human TNF-alpha.

[accordions]
[accordion title= “Cell Research“]

Objective: Adalimumab induces apoptosis of THP-1 cells. Concentrations: 10μg/mL. Incubation Time: 6, 12, 18, 24, 30 hours. Method: THP-1 cells (0.5×106) were incubated with anti-FcRI mAb and anti-FcRII mAb, and then cultured with adalimumab, infliximab, huIgG or vehicle (PBS) alone as indicated. LPS (1μg/mL) was added in all culture conditions. Apoptosis was analyzed at different time points by staining with annexin V-FITC and propidium iodide, Apo2.7-PE-conjugated antibody, or 7AAD.

[/accordion]

[accordions]
[accordion title= “Animal Research“]

Objective: The distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. Formulation: PBS. Dosages: 2 mg/kg

[/accordion]

[accordions]
[accordion title= “References and Literature“]

1. Mease PJ, et al. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. Expert Opin Biol Ther. 2005 Nov;5(11):1491-504.2. Elsakkar MG, et al. Adalimumab ameliorates OVA-induced airway inflammation in mice: Role of CD4(+) CD25(+) FOXP3(+) regulatory T-cells. Eur J Pharmacol. 2016 Sep 5;786:100-108.

[/accordion]

[accordions]
[accordion title= “Chemical Properties“]

[/accordion]